• Home
  • Journalists
    • Headlines
  • Community
    • Businesses
    • Jobs
    • Learning
    • Marketplace
  • Store
(@)

FDA Panel Rejects Use of MDMA for Treatment of PTSD

An independent group of experts expressed concerns that the data from clinical trials did not outweigh risks for treatment of post-traumatic stress disorder.

Andrew Jacobs
Author: Andrew Jacobs

Written by

Andrew Jacobs

in

Drug Abuse and Traffic, Drugs (Pharmaceuticals), Ecstasy (Drug), Food and Drug Administration, Institute for Clinical and Economic Review, Justice Department, Lykos Therapeutics, Medicine and Health, Mental Health and Disorders, Multidisciplinary Assn for Psychedelic Studies, Placebos, Post-Traumatic Stress Disorder, Psychedelic and Hallucinogenic Drugs, Psychiatry and Psychiatrists, Regulation and Deregulation of Industry, Therapy and Rehabilitation, Veterans
←Alarming Report Warns Of ‘Greatest Threat To American Democracy You’ve Never Heard Of’
Trump Asks For Gag Order To Be Lifted Before Debate With Biden→

More posts

  • Oracle jumps after Q3 results exceed expectations, boost to sales guidance

  • Stocks close lower in volatile trading session, crude oil falls after trimming steeper losses

  • Ted Cruz, Tucker Carlson reignite feud over Iran war

  • WATCH: Waymo vehicle stops inside railway crossing gate

About Us


Support Us

Trademark & Copyright 1998 – 2025 · MOSAEC

  • Facebook
  • Instagram
  • LinkedIn
  • YouTube